PPARgamma activation extinguishes smoking carcinogen by inhibiting NNK-mediated proliferation

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Cigarette smoking contains potent carcinogens like 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).
• Peroxisome proliferator-activated receptor (PPAR)gamma activation shows potential in arresting lung cancer growth.
• PPARgamma is frequently overexpressed in human lung tumors and cancer cell lines.

Purpose of the Study:

• To investigate the hypothesis that PPARgamma activation inhibits NNK-mediated proliferation of lung cancer cells.
• To elucidate the molecular mechanisms underlying PPARgamma's role in combating NNK-induced lung cancer.

Main Methods:

• Assessed PPARgamma expression in human lung tumor tissues and cancer cell lines.
• Treated lung cancer cells with NNK and troglitazone (a PPARgamma activator).
• Monitored cell proliferation, gene/protein expression (HO-1, Bcl-2, c-IAP2, Bad, p21), and PPARgamma transcriptional activity.
• Utilized a PPARgamma dominant-negative inhibitor to confirm pathway dependency.

Main Results:

• PPARgamma was highly expressed in 94.7% of lung tumor tissues and abundant in lung cancer cell lines.
• Troglitazone dose-dependently inhibited NNK-induced proliferation in PPARgamma-expressing lung cancer cells.
• Troglitazone blocked NNK-induced HO-1, Bcl-2, and c-IAP2 upregulation, restored Bad activity, and altered p21 localization.
• Troglitazone enhanced PPARgamma transcriptional activity, and its effects were abolished by a PPARgamma dominant-negative inhibitor.

Conclusions:

• PPARgamma activation, exemplified by troglitazone treatment, effectively inhibits NNK-induced lung cancer cell proliferation.
• This study reveals a novel molecular pathway where PPARgamma activation counteracts cigarette smoking-related lung carcinogenesis.
• Findings support targeting PPARgamma as a potential therapeutic strategy for lung cancer prevention and treatment.